Mural Oncology to Participate in Two Upcoming Investor Conferences
Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced its participation in two upcoming investor conferences. The company will attend the Jefferies London Healthcare Conference for one-on-one meetings on November 19-20, 2024, and the Piper Sandler 36th Annual Healthcare Conference for a fireside chat on December 9, 2024, at 9:30 a.m. ET. Key management team members participating include CEO Caroline Loew, Chief Medical Officer Vicki Goodman, and CFO Adam Cutler. A webcast of the Piper Sandler presentation will be available on the company's investor relations website.
Mural Oncology (Nasdaq: MURA), un'azienda clinica nel campo dell'immuno-oncologia, ha annunciato la propria partecipazione a due prossime conferenze per investitori. L'azienda parteciperà alla Jefferies London Healthcare Conference per incontri one-to-one il 19-20 novembre 2024, e alla Piper Sandler 36th Annual Healthcare Conference per una chiacchierata informale il 9 dicembre 2024, alle 9:30 a.m. ET. Partecipano membri chiave del team di gestione, tra cui l'AD Caroline Loew, il Chief Medical Officer Vicki Goodman e il CFO Adam Cutler. Una trasmissione web della presentazione di Piper Sandler sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda.
Mural Oncology (Nasdaq: MURA), una empresa de inmuno-oncología en etapa clínica, ha anunciado su participación en dos próximas conferencias para inversionistas. La empresa asistirá a la Jefferies London Healthcare Conference para reuniones uno a uno el 19 y 20 de noviembre de 2024, y a la Piper Sandler 36th Annual Healthcare Conference para una charla informal el 9 de diciembre de 2024, a las 9:30 a.m. ET. Participarán miembros clave del equipo de gestión, incluyendo a la CEO Caroline Loew, la directora médica Vicki Goodman y el CFO Adam Cutler. Una transmisión web de la presentación de Piper Sandler estará disponible en el sitio web de relaciones con inversionistas de la empresa.
뮤럴 종양학 (Nasdaq: MURA), 임상 단계의 면역 종양학 회사,는 다가오는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 2024년 11월 19-20일 제퍼리스 런던 헬스케어 컨퍼런스에 일대일 회의를 위해 참석하며, 2024년 12월 9일 오전 9시 30분 ET에 파이퍼 샌들러 제36회 연례 헬스케어 컨퍼런스에서 소규모 대화에 참여합니다. 참여하는 주요 경영진에는 CEO 캐롤라인 로우, 최고 의료 책임자 비키 굿맨, CFO 아담 커틀러가 포함됩니다. 파이퍼 샌들러 발표의 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공될 예정입니다.
Mural Oncology (Nasdaq: MURA), une entreprise d'immuno-oncologie en phase clinique, a annoncé sa participation à deux conférences pour investisseurs à venir. L'entreprise assistera à la Jefferies London Healthcare Conference pour des réunions individuelles les 19 et 20 novembre 2024, et à la Piper Sandler 36th Annual Healthcare Conference pour une discussion informelle le 9 décembre 2024, à 9h30 ET. Les membres clés de l'équipe de direction participant incluent la PDG Caroline Loew, la médecin en chef Vicki Goodman et le directeur financier Adam Cutler. Un webinaire de la présentation de Piper Sandler sera disponible sur le site des relations investisseurs de l’entreprise.
Mural Oncology (Nasdaq: MURA), ein Unternehmen für immunonkologische klinische Studien, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird an der Jefferies London Healthcare Conference am 19. und 20. November 2024 für persönliche Gespräche teilnehmen und an der Piper Sandler 36th Annual Healthcare Conference am 9. Dezember 2024 um 9:30 Uhr ET für ein informelles Gespräch teilnehmen. Zu den teilnehmenden Mitgliedern des Management-Teams gehören CEO Caroline Loew, Chief Medical Officer Vicki Goodman und CFO Adam Cutler. Ein Webcast der Piper Sandler-Präsentation wird auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of the management team will participate in two upcoming investor conferences.
Jefferies London Healthcare Conference
1x1 meetings with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD, Chief Medical Officer, Adam Cutler, Chief Financial Officer
Date: Tuesday, November 19-Wednesday, November 20, 2024
Piper Sandler 36th Annual Healthcare Conference
Fireside chat with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD, Chief Medical Officer, and Adam Cutler, Chief Financial Officer
Date: Wednesday, December 9, 2024
Time: 9:30 a.m. ET
A webcast of the presentation will be available at https://ir.muraloncology.com/.
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential, and reach, of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in platinum-resistant ovarian cancer and mucosal melanoma reading out in the first half of 2025. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Contact:
Katie Sullivan
katie.sullivan@muraloncology.com
FAQ
When is Mural Oncology (MURA) presenting at the Piper Sandler Healthcare Conference?
Which investor conferences will Mural Oncology (MURA) attend in late 2024?
Where can I watch Mural Oncology's (MURA) Piper Sandler Conference presentation?
Which executives from Mural Oncology (MURA) will attend these investor conferences?
